1. Home
  2. MCRB
  3. MCRB News

Latest Seres Therapeutics Inc. (MCRB) News on May 10, 2025

MCRB

MT Newswires

2 days ago

Seres Therapeutics Shares Fall After Downgrade From Chardan

MCRB

MT Newswires

2 days ago

Chardan Downgrades Seres Therapeutics to Neutral From Buy, Adjusts Price Target to $6 From $25

MCRB

Associated Press Finance

3 days ago

Seres Therapeutics: Q1 Earnings Snapshot

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
MCRB

GlobeNewswire

3 days ago

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases
MCRB

GlobeNewswire

11 days ago

Seres Therapeutics Presents Data at the 2025 Digestive Disease Week Conference Highlighting the Potential for Live Biotherapeutics to Treat Inflammatory and Immune Diseases

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025
MCRB

GlobeNewswire

17 days ago

Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround
MCRB

Zacks

23 days ago

Down -48.7% in 4 Weeks, Here's Why Seres Therapeutics (MCRB) Looks Ripe for a Turnaround

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?
MCRB

Simply Wall St.

2 months ago

Seres Therapeutics, Inc. (NASDAQ:MCRB): Are Analysts Optimistic?

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...
MCRB

GuruFocus.com

2 months ago

Seres Therapeutics Inc (MCRB) Q4 2024 Earnings Call Highlights: Financial Improvements and ...

MCRB

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Seres Therapeutics Inc Earnings Call

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
MCRB

GlobeNewswire

2 months ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025
MCRB

GlobeNewswire

2 months ago

Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach
MCRB

GlobeNewswire

2 months ago

Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

MCRB

MT Newswires

4 months ago

Seres Therapeutics Receives First of 2 Installments Related to VOWST Sale

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale
MCRB

GlobeNewswire

4 months ago

Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

Seres announces new translational biomarker results from SER-155 Phase 1b study
MCRB

TipRanks

4 months ago

Seres announces new translational biomarker results from SER-155 Phase 1b study

MCRB

MT Newswires

4 months ago

Seres Therapeutics Reports 'Positive Impact' in SER-155 Early Trial; Cash Runway Extended

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates
MCRB

GlobeNewswire

4 months ago

Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable
MCRB

Simply Wall St.

4 months ago

The past three years for Seres Therapeutics (NASDAQ:MCRB) investors has not been profitable

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference
MCRB

TipRanks

5 months ago

Seres Therapeutics to highlight plans for SER-155 at JPMorgan conference

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference
MCRB

GlobeNewswire

5 months ago

Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference

Seres’ SER-155 gains breakthrough status for BSIs reduction
MCRB

Pharmaceutical Technology

5 months ago

Seres’ SER-155 gains breakthrough status for BSIs reduction

MCRB

MT Newswires

5 months ago

Seres Therapeutics Says FDA Grants Breakthrough Therapy Status to SER-155

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
MCRB

GlobeNewswire

5 months ago

FDA Grants Breakthrough Therapy Designation to Seres Therapeutics’ SER-155 for Reduction of Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
MCRB

GlobeNewswire

6 months ago

Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)
MCRB

Simply Wall St.

6 months ago

Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
MCRB

GuruFocus.com

6 months ago

Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...

MCRB

Associated Press Finance

6 months ago

Seres Therapeutics: Q3 Earnings Snapshot

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
MCRB

GlobeNewswire

6 months ago

Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
MCRB

GlobeNewswire

6 months ago

Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024

MCRB

MT Newswires

7 months ago

JPMorgan Downgrades Seres Therapeutics to Underweight

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
MCRB

Simply Wall St.

7 months ago

Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value

MCRB

MT Newswires

7 months ago

Seres Therapeutics Files Registration for Resale of Shares by Societe des Produits Nestle

MCRB

MT Newswires

7 months ago

Seres Therapeutics Completes Sale of VOWST Unit to Societe des Produits Nestle

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
MCRB

GlobeNewswire

7 months ago

Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A

MCRB

MT Newswires

7 months ago

Seres Therapeutics Shareholders Approve Sale of VOWST Unit to Nestle; Shares Rise

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
MCRB

GlobeNewswire

7 months ago

Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
MCRB

GlobeNewswire

8 months ago

Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
MCRB

GlobeNewswire

8 months ago

Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)

After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
MCRB

Zacks

8 months ago

After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)

Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
MCRB

Zacks

9 months ago

Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now

MCRB

Thomson Reuters StreetEvents

9 months ago

Q2 2024 Seres Therapeutics Inc Earnings Call

MCRB

Associated Press Finance

9 months ago

Seres Therapeutics: Q2 Earnings Snapshot

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
MCRB

GlobeNewswire

9 months ago

Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
MCRB

GlobeNewswire

9 months ago

Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
MCRB

GlobeNewswire

9 months ago

Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024

Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years
MCRB

Simply Wall St.

10 months ago

Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MCRB

GlobeNewswire

a year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRB

MT Newswires

a year ago

Seres Therapeutics to Sell Vowst Assets to Nestle Health Science

Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle
MCRB

BioPharma Dive

a year ago

Seres, indebted and in need of cash, agrees to sell microbiome pill to Nestle

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023
MCRB

PR Newswire

a year ago

Nestlé Health Science agrees to acquire global rights to VOWST®, product it launched in June 2023

MCRB

GlobeNewswire

a year ago

Seres Therapeutics Enters Into Memorandum of Understanding For Vowst™ Asset Sale to Nestlé Health Science

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript
MCRB

Insider Monkey

a year ago

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q1 2024 Earnings Call Transcript

MCRB

MT Newswires

a year ago

Oppenheimer Adjusts Seres Therapeutics Price Target to $4 From $5, Maintains Outperform Rating

Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
MCRB

Simply Wall St.

a year ago

Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)

MCRB

MT Newswires

a year ago

Chardan Adjusts Price Target on Seres Therapeutics to $6 From $8, Keeps Buy Rating

MCRB

GuruFocus.com

a year ago

Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...

MCRB

GuruFocus.com

a year ago

Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates

MCRB

Associated Press Finance

a year ago

Seres Therapeutics: Q1 Earnings Snapshot

MCRB

Business Wire

a year ago

Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

MCRB

Business Wire

a year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRB

Business Wire

a year ago

Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024

MCRB

Business Wire

a year ago

Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT

Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now
MCRB

Simply Wall St.

a year ago

Increases to Seres Therapeutics, Inc.'s (NASDAQ:MCRB) CEO Compensation Might Cool off for now

MCRB

Business Wire

a year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MCRB

Business Wire

a year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oversold NASDAQ Stocks To Buy Right Now
MCRB

Insider Monkey

a year ago

11 Oversold NASDAQ Stocks To Buy Right Now

11 Oversold Healthcare Stocks To Buy Right Now
MCRB

Insider Monkey

a year ago

11 Oversold Healthcare Stocks To Buy Right Now

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript
MCRB

Insider Monkey

a year ago

Seres Therapeutics, Inc. (NASDAQ:MCRB) Q4 2023 Earnings Call Transcript

MCRB

Thomson Reuters StreetEvents

a year ago

Q4 2023 Seres Therapeutics Inc Earnings Call

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023
MCRB

GuruFocus.com

a year ago

Seres Therapeutics Inc (MCRB) Reports Encouraging Sales Growth and Strategic Cost Savings in 2023

MCRB

Business Wire

a year ago

Seres Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

MCRB

Business Wire

a year ago

Seres Therapeutics to Host Fourth Quarter 2023 Financial Results and Operational Progress Conference Call and Webcast on March 5, 2024

MCRB

Business Wire

a year ago

Seres Therapeutics to Participate in Cowen 44th Annual Healthcare Conference

MCRB

Business Wire

a year ago

Seres Therapeutics Announces the Appointment of Marella Thorell as Chief Financial Officer and the Retirement of David Arkowitz

Community West Bancshares Reports Full Year Earnings Amid Merger Developments
MCRB

GuruFocus.com

a year ago

Community West Bancshares Reports Full Year Earnings Amid Merger Developments

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion
MCRB

Zacks

a year ago

Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion

MCRB

Associated Press Finance

a year ago

Bridgewater: Q4 Earnings Snapshot

Analysts Have Made A Financial Statement On Central Valley Community Bancorp's (NASDAQ:CVCY) Full-Year Report
MCRB

Simply Wall St.

a year ago

Analysts Have Made A Financial Statement On Central Valley Community Bancorp's (NASDAQ:CVCY) Full-Year Report

Hear from Dale Schwartz, Founder & CEO of Pinstripes Holdings Inc. Live at ICR Conference 2024
MCRB

IPO-Edge.com

a year ago

Hear from Dale Schwartz, Founder & CEO of Pinstripes Holdings Inc. Live at ICR Conference 2024

Institutional investors own a significant stake of 48% in AVITA Medical, Inc. (NASDAQ:RCEL)
MCRB

Simply Wall St.

a year ago

Institutional investors own a significant stake of 48% in AVITA Medical, Inc. (NASDAQ:RCEL)

MCRB

Business Wire

a year ago

Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
MCRB

Zacks

a year ago

Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?

The Vintage IKEA Pieces Everyone Wants—and 3 Great Finds Still Under the Radar
MCRB

The Wall Street Journal

a year ago

The Vintage IKEA Pieces Everyone Wants—and 3 Great Finds Still Under the Radar

Rigetti Computing Awarded Innovate UK Grant to Develop Quantum Machine Learning Techniques for Financial Data Streams
MCRB

GlobeNewswire

a year ago

Rigetti Computing Awarded Innovate UK Grant to Develop Quantum Machine Learning Techniques for Financial Data Streams

MCRB

Business Wire

a year ago

Seres Therapeutics Announces VOWST™ Commercial Launch Update and US FDA Fast Track Designation for SER-155

Do Third Coast Bancshares' (NASDAQ:TCBX) Earnings Warrant Your Attention?
MCRB

Simply Wall St.

a year ago

Do Third Coast Bancshares' (NASDAQ:TCBX) Earnings Warrant Your Attention?

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue
MCRB

GlobeNewswire

a year ago

scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX® Revenue

MCRB

Business Wire

a year ago

Seres Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Crunch Fitness, Appian, Pinstripes CEOs and more: C-Suite Insights
MCRB

Yahoo Finance Video

a year ago

Crunch Fitness, Appian, Pinstripes CEOs and more: C-Suite Insights

Xerox layoffs, Xponential Fitness downgrade: Trending Stocks
MCRB

Yahoo Finance Video

a year ago

Xerox layoffs, Xponential Fitness downgrade: Trending Stocks

Ceragon Networks to Participate in the Needham Growth Conference
MCRB

PR Newswire

a year ago

Ceragon Networks to Participate in the Needham Growth Conference

Pinstripes looking to expand internationally, CEO explains
MCRB

Yahoo Finance Video

a year ago

Pinstripes looking to expand internationally, CEO explains

Owning 47% shares,institutional owners seem interested in Hallador Energy Company (NASDAQ:HNRG),
MCRB

Simply Wall St.

a year ago

Owning 47% shares,institutional owners seem interested in Hallador Energy Company (NASDAQ:HNRG),

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study
MCRB

GlobeNewswire

a year ago

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Strength Seen in Orange County Bancorp, Inc. (OBT): Can Its 6.9% Jump Turn into More Strength?
MCRB

Zacks

a year ago

Strength Seen in Orange County Bancorp, Inc. (OBT): Can Its 6.9% Jump Turn into More Strength?

ParkUSA, A Northwest Pipe Company, launches new website
MCRB

PR Newswire

a year ago

ParkUSA, A Northwest Pipe Company, launches new website

5 Hospital Stocks to Watch Amid Promising Industry Trends
MCRB

Zacks

a year ago

5 Hospital Stocks to Watch Amid Promising Industry Trends

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development
MCRB

GlobeNewswire

a year ago

Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

With 74% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big guns
MCRB

Simply Wall St.

a year ago

With 74% institutional ownership, OptimizeRx Corporation (NASDAQ:OPRX) is a favorite amongst the big guns

Share on Social Networks: